23 March, 2010
FDA in Saudi Arabia suspends diabetes drug Avandia
Distribution of Avandia has been suspended for six months by the Saudi Food and Drug Authority (SFDA), linking use of the diabetes drug to adverse cardiovascular effects. A decision has not been made whether a permanent Avandia recall will follow.
“The S FDA Committee… Continue reading Avandia suspended from market by Saudi FDACategory: Avandia Cardiovascular Risk | Avandia News | Avandia Recall | Avandia Safety | Avandia Side Effects
23 March, 2010
Avandia research study shows experts defending the diabetes drug had financial ties to GlaxoSmithKline
They discovered that 94% of the authors who defended Avandia (rosiglitazone) had financial ties to drug makers. Almost half of the financial ties amounted to a conflict of interest… Continue reading Avandia heart attack risk researchers had financial ties to drug maker, conflicts of interestCategory: Avandia Cardiovascular Risk | Avandia News | Avandia Safety | Avandia Side Effects
15 March, 2010
FDA Issues Safety Alert on Avandia
The U.S. Food and Drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes. Safety data from controlled clinical trials have shown that there is a potentially significant increase in the risk of heart attack and heart-related… Continue reading Avandia FDA Safety Alert - April 2009Category: Avandia FDA
11 March, 2010
Avandia heart side effects lawsuits could cost GlaxoSmithKline up to $6 billion, said UBS analysts in a note made public last week.
The UBS note follows a highly critical report on the drug by the U.S. Senate Finance Committee. Over 13,000 Avandia personal injury and wrongful death lawsuits currently are pending against the GSK… Continue reading Avandia side effects lawsuit settlements could top $6 billion in liability for GSKCategory: Avandia Lawsuit | Avandia News | Avandia Senate Report | Avandia Settlements | Avandia Side Effects | Avandia Warning
6 March, 2010
Avandia drug company GlaxoSmithKline defends its popular diabetes drug in a 30-page “white paper” released February 24 rejecting a recent Senate Report stating that GSK downplayed the safety risks of their diabetes treatment Avandia. The prescription drug maker attacks the Senate Finance Committee’s January 2010 report on Avandia, claiming it is inaccurate, unbalanced and gives Continue reading Avandia maker GlaxoSmithKline releases "White Paper Response" to Senate Report on AvandiaCategory: Avandia FDA | Avandia News | Avandia Recall | Avandia Safety | Avandia Senate Report